Literature DB >> 19746656

Time course of enrofloxacin and its active metabolite in peripheral leukocytes of dogs.

A Boeckh1, D Boothe, S Wilkie, S Jones.   

Abstract

The accumulation of fluoroquinolones in peripheral leukocytes is well established for several members of this family of drugs. This study documented accumulation of enrofloxacin and its active metabolite, ciprofloxacin, in canine peripheral leukocytes after oral administration at 7.5, 10, or 20 mg/kg, doses that are within the currently approved label of Baytril (Bayer Corporation Animal Health, Shawnee Mission, KS) in the United States. Accumulation index, as defined by C(max) in white blood cells (WBCs) divided by C(max) in plasma at the same time points, ranged from 47-fold to 63-fold for enrofloxacin and 28- to 35-fold for ciprofloxacin. Time course of both enrofloxacin and ciprofloxacin in WBCs paralleled the time course in plasma. Disappearance half-life of ciprofloxacin from WBCs was significantly (P = .001) longer than was enrofloxacin (P= .015) for all doses studied. The accumulation of enrofloxacin in peripheral leukocytes may contribute to the antimicrobial efficacy of this compound.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 19746656

Source DB:  PubMed          Journal:  Vet Ther        ISSN: 1528-3593


  2 in total

1.  Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.

Authors:  D York; S S Withers; K D Watson; K W Seo; R B Rebhun
Journal:  Vet Comp Oncol       Date:  2016-06-23       Impact factor: 2.613

2.  Enhanced intracellular delivery and antibacterial efficacy of enrofloxacin-loaded docosanoic acid solid lipid nanoparticles against intracellular Salmonella.

Authors:  Shuyu Xie; Fei Yang; Yanfei Tao; Dongmei Chen; Wei Qu; Lingli Huang; Zhenli Liu; Yuanhu Pan; Zonghui Yuan
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.